Cerus Stock Price, News & Analysis

Cerus Corporation (Nasdaq: CERS) reported record revenues for Q4 2020 at $33.6 million, totaling $114.2 million for the year. Product revenue increased 35% in Q4 and 23% for the year. Despite a net loss of $14.4 million for Q4, the loss narrowed compared to the previous year. The company has projected 2021 product revenue guidance between $106 million and $110 million, showing an expected 15% to 20% increase. Notable achievements include FDA approval for a new blood product and a new joint venture in China.

Cerus Corporation (Nasdaq: CERS) has formed a joint venture, Cerus ZBK Biomedical (CEZB), with Shandong Zhongbaokang Medical Implements Co. Ltd. to develop and commercialize the INTERCEPT Blood System for platelets and red blood cells in China. Cerus will hold a 51% stake, while ZBK will leverage its local expertise and manufacturing capabilities. This collaboration aims to address China's growing blood transfusion market, which sees over 23 million red blood cell collections annually. The joint venture is expected to accelerate access to safer blood components in the region.

Cerus Corporation (Nasdaq: CERS) will announce its Q4 and full year 2020 financial results on February 25, 2021, post-market close. A conference call is scheduled for 4:30 PM ET the same day, where management will discuss the financial results and provide a business overview and outlook. Interested parties can access the call via the Investor Relations page or by phone. A replay will be available shortly after the call.

Cerus focuses on ensuring safe blood supply through the INTERCEPT Blood System, which has received both CE Mark and FDA approval.

Cerus Corporation (Nasdaq: CERS) has announced that CEO William ‘Obi’ Greenman and CFO Kevin D. Green will participate in two upcoming conferences. The first event is the BTIG Virtual MedTech Conference on February 17 at 1:30 PM ET, followed by the Cowen 41st Annual Health Care Conference on March 1 at 2:40 PM ET. Both events will be webcast live, with replays available for two weeks post-event. Cerus focuses on enhancing blood safety through its INTERCEPT Blood System, which has received both CE mark and FDA approval for pathogen reduction in platelets and plasma.

Cerus Corporation (Nasdaq: CERS) reported preliminary product revenue for Q4 2020 at $28.2 million, a 35% increase from $20.9 million in Q4 2019, which positions it for a total 2020 revenue of $91.9 million. This is above the prior guidance range of $89 million to $91 million. The company anticipates 2021 revenue of $106 million to $110 million, reflecting 15% to 20% growth driven by strong demand for INTERCEPT platelet kits despite ongoing COVID-19 impacts. Additionally, 2021 will see the first sales of a new biologic therapeutic product.

Cerus Corporation (Nasdaq: CERS) announced a three-year contract with HemoMinas Foundation in Brazil to supply the INTERCEPT Blood System for platelets. HemoMinas, the largest blood service in Minas Gerais, distributes around 25,000 platelet doses annually. The INTERCEPT system is vital for reducing pathogen risks including Zika and Dengue viruses. This contract underscores the importance of pathogen reduction in Brazil's blood safety strategy. The INTERCEPT system is the only one approved by ANVISA for commercial use in the country, supporting over 3.7 million collected blood components each year.

Cerus Corporation (Nasdaq: CERS) announced a clinical study on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma, presented by Dr. Nina Khanna at the American Society of Hematology Annual Meeting on December 5, 2020. The study, involving 15 patients treated with INTERCEPT CCP, showed a 93.3% survival rate at day 28, compared to 20% in the control group. Conducted in collaboration with various research institutions, the findings highlight the potential of INTERCEPT technology in combating COVID-19 and improving patient outcomes.

Cerus Corporation (Nasdaq: CERS) announced FDA approval for the INTERCEPT Blood System for Cryoprecipitation, used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex, critical for treating massive hemorrhage. This product, effective for up to 5 days at room temperature, holds FDA Breakthrough Device designation, signaling significant potential in emergency care. Cerus plans to launch in select states in 2021 and expand nationally in 2022, contingent on further regulatory approvals. This approval aligns with Cerus' mission to set pathogen reduction as the global standard for transfused blood components.

Cerus Corporation (Nasdaq: CERS) announced participation in two upcoming conferences: the Stifel Virtual Healthcare Conference on November 16 at 1:20 PM ET and the Stephens Annual Investment Conference on November 19 at 3:00 PM ET. Key executives, William ‘Obi’ Greenman and Kevin D. Green, will represent the company. A live webcast will be available on the Investor Relations page of Cerus' website, with replays accessible for about two weeks. Cerus focuses on blood safety technologies through its INTERCEPT Blood System.